GLP-1 Market
LLY $1188.72 ▲ +2.7% NVO $38.26 ▲ +1.9% PFE $28.00 ▲ +1.8% VKTX $28.54 ▲ +0.6% KLRA $10.53 ▼ -2.8% GPCR $26.68 ▼ -2.9% RHHBY $53.97 ▲ +2.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

ALXN2220

ALXN2220

Company
Neurimmune AG
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 8, 2026

Trial details
  • Active, not recruiting NCT NCT06183931

    Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

    Not yet reported Alexion Pharmaceuticals, Inc. 1181 participants Est. completion 2028-04-05 213 sites Stand-alone
    Other conditions: Transthyretin Amyloid Cardiomyopathy
    View official trial listing →
  • Active, not recruiting NCT NCT07213583

    Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM

    Not yet reported Neurimmune AG 35 participants Est. completion 2026-10-31 6 sites Stand-alone
    Other conditions: Amyloid Transthyretin Cardiomyopathy
    View official trial listing →
  • Active, not recruiting NCT NCT07608354

    A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

    Not yet reported AstraZeneca 326 participants Est. completion 2029-02-06 76 sites Stand-alone
    Other conditions: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    View official trial listing →
  • Not yet recruiting NCT NCT07789483

    An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

    Not yet reported Alexion Pharmaceuticals, Inc. 1180 participants Est. completion 2030-07-11 195 sites Stand-alone
    Other conditions: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.